Quick Answer
Zentalis Pharmaceuticals, Inc. reported Stockholders Equity of $216.20 million for the year ending 2025.
- Zentalis Pharmaceuticals, Inc. showed a decrease of -35.9% in Stockholders Equity from 2024 to 2025.
- This data is from Zentalis Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2020: $308.58 million | Q1 2021: $268.39 million | Q2 2021: $223.85 million | Q3 2021: $393.43 million | Q4 2021: $363.95 million | Q1 2022: $315.30 million | Q2 2022: $472.49 million | Q3 2022: $428.50 million | Q1 2023: $385.49 million | Q2 2023: $523.14 million | Q3 2023: $481.77 million | Q1 2024: $458.77 million | Q2 2024: $382.58 million | Q3 2024: $354.33 million | Q1 2025: $295.38 million | Q2 2025: $274.50 million | Q3 2025: $252.87 million.
- Over the full 4 years of available data (2022 to 2025), Zentalis Pharmaceuticals, Inc.'s Stockholders Equity has declined by 50.2%.
- Historical annual values: Fiscal year 2025: $216.20 million | Fiscal year 2024: $337.19 million | Fiscal year 2023: $437.28 million | Fiscal year 2022: $433.80 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: